James Murphy - Decibel Therapeutics Principal CFO

Insider

James Murphy is Principal CFO of Decibel Therapeutics
Age 66
Phone617 370 8701
Webhttps://www.decibeltx.com

Decibel Therapeutics Management Efficiency

The company has return on total asset (ROA) of (0.3265) % which means that it has lost $0.3265 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7676) %, meaning that it created substantial loss on money invested by shareholders. Decibel Therapeutics' management efficiency ratios could be used to measure how well Decibel Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
Decibel Therapeutics currently holds 14.05 M in liabilities with Debt to Equity (D/E) ratio of 0.14, which may suggest the company is not taking enough advantage from borrowing. Decibel Therapeutics has a current ratio of 6.06, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Decibel Therapeutics' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Alfredo CastroIkena Oncology
N/A
Benjamin DakeAerovate Therapeutics
49
Brian MDRezolute
50
Lauren WhiteC4 Therapeutics
N/A
Brian SullivanCelcuity LLC
63
, MBAMolecular Partners AG
51
Sheri SmithCelcuity LLC
N/A
Evan HeckerIkena Oncology
N/A
Erick MDAcrivon Therapeutics, Common
67
Man MBAAdagene
48
MBA MDIkena Oncology
59
Guizhong LiuAdagene
54
Seth LewisMolecular Partners AG
N/A
Michelle ZhangIkena Oncology
N/A
Fangyong DuAdagene
54
Jc MDAdagene
60
Behrad DerakhshanEdgewise Therapeutics
45
Kelly SchickC4 Therapeutics
45
Cynthia SeidelDuganWerewolf Therapeutics
65
MD MBARezolute
N/A
Michael PitznerMolecular Partners AG
N/A
Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts. Decibel Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 62 people. Decibel Therapeutics (DBTX) is traded on NASDAQ Exchange in USA and employs 68 people.

Management Performance

Decibel Therapeutics Leadership Team

Elected by the shareholders, the Decibel Therapeutics' board of directors comprises two types of representatives: Decibel Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Decibel. The board's role is to monitor Decibel Therapeutics' management team and ensure that shareholders' interests are well served. Decibel Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Decibel Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Anna MA, Ex Officer
Gabriel Corfas, CoFounder Board
James Murphy, Principal CFO
Charles Liberman, CoFounder Board
John Lee, Chief Officer
Joe Burns, VP Discovery
Elaine Cope, VP Operations
Ulrich Mller, CoFounder Board
Laurence Reid, CEO Pres
Albert Edge, CoFounder Board

Decibel Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Decibel Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Other Consideration for investing in Decibel Stock

If you are still planning to invest in Decibel Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Decibel Therapeutics' history and understand the potential risks before investing.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios